Physician profile
Deborah C Siman
NPI 1639128051
$4,127.35
in general payments reported to CMS, 2019-2025
31 companies · $573 in 2025
The $573 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $374 · 2021: $762 · 2022: $503 · 2023: $1,095 · 2024: $344 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.54 |
| Education | $211.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $790.02 | 2021-2025 | |
| Abbvie INC. | $727.28 | 2019-2024 | Lo Loestrin Fe |
| Astellas Pharma US INC | $561.17 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $472.87 | 2019-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Pfizer INC. | $200.89 | 2019-2025 | |
| Exeltis, USA INC. | $193.22 | 2023-2025 | Slynd |
| Vertical Pharmaceuticals, LLC | $134.87 | 2019-2020 | |
| Evofem Biosciences, INC. | $122.60 | 2020-2024 | |
| Therapeuticsmd, INC. | $102.96 | 2020-2021 | |
| Intuitive Surgical, INC. | $97.36 | 2023 | Da Vinci Surgical System |
| Coopersurgical, INC. | $85.88 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $78.59 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $73.88 | 2019-2021 | |
| Shield Therapeutics INC | $57.54 | 2023 | Accrufer |
| Lilly USA, LLC | $52.52 | 2025 | Zepbound, Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $48.77 | 2021 | |
| Myovant Sciences INC. | $41.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.93 | 2019-2020 | |
| Coloplast Corp | $29.84 | 2019 | |
| Sumitomo Pharma America, INC. | $25.92 | 2025 | Gemtesa |
| Allergan, INC. | $24.92 | 2019-2020 | |
| Radius Health, INC. | $22.86 | 2019 | |
| Duchesnay USA Incorporated | $22.21 | 2019 | |
| Agile Therapeutics, INC. | $21.12 | 2021 | |
| Exact Sciences Corporation | $18.43 | 2023 | Cologuard Collection Kit |
| Ascend Therapeutics US, LLC | $16.00 | 2022 | |
| Aspira Women'S Health INC | $13.75 | 2020 | |
| Medicem INC. | $13.53 | 2021 | |
| Millicent US INC | $13.35 | 2024 | |
| Organon LLC | $13.24 | 2023 | Nexplanon |
| Mission Pharmacal Company | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Siman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.